No exaggerated expectations for innovative medicines

The reality of innovative medicines in Slovakia, as highlighted by the Health Policy Institute (ÚHP), is far less dramatic than often portrayed in public discourse. While the promise of groundbreaking treatments is alluring, the data reveals a more nuanced picture: most new drugs offer only marginal improvements in health outcomes.

“

Nové či inovatívne lieky štandardne predlžujú život v plnom zdraví o pár mesiacov.

Out of 95 drugs assessed recently, a mere 22 provided patients with over a year of additional healthy life. This stark statistic underscores a broader international trend where innovative drugs often yield incremental benefits, typically measured in months rather than years. The notion that a plethora of life-saving drugs are readily available, pending only insurance approval, is largely a misconception fueled by media narratives and a lack of transparent data on actual benefits.

“

Viac ako polovica liekov, ktoré medzi rokmi 2011 a 2017 vstúpili na nemecký trh, nepreukázala podľa nemeckej liekovej agentúry prínos v porovnaní s liečbou dostupnou predtým.

The ÚHP points out that the public discussion often fixates on the unavailability of specific drugs, neglecting a crucial conversation about their actual value and benefits. This imbalance hinders rational decision-making and policy development. To address this, the institute advocates for regular, publicly accessible reports detailing drug costs and their proven health benefits.

“

Málokedy sa stáva, že na trh príde liek, ktorý zásadne zmení prognózu pacienta.

From a Slovak perspective, this information is vital. It challenges the often-inflated expectations surrounding new pharmaceuticals and encourages a more critical evaluation of healthcare spending. While access to effective treatments is paramount, ensuring that public funds are directed towards drugs that offer substantial, measurable improvements in quality and length of life is equally important. This data-driven approach, promoted by the ÚHP, aims to shift the focus from emotional appeals to evidence-based policy, ultimately benefiting the healthcare system and patients alike.

“

Potrebujeme verejnú diskusiu posunúť od poukazovania na nedostupnosť liekov k ich prínosom.